Emerging evidences have reported that SKP2 is frequently overexpressed in prostate cancer [10], melanoma [11], nasopharyngeal carcinoma [12], and breast cancer [13], and associated with poor prognosis by enhancing tumor progression [7]. Here, SKP2 is linked to prostate carcinoma.